Mistake 3: Ignoring peptide receptor competition
Recalls & Warnings April 26, 2013 Seller of Immune, Cholesterol, Liver and Blood Sugar Products Warned For Drug Claims On March 20, 2013, the FDA issued a warning letter to Birkdale Medicinals LLC, following a review of the company's website which found statements made about Birkdale products, including Immune Response 247, Cholestat, Silymarin 81 and LevelStat, to be drug claims
The College of Physicians and Surgeons of British Columbia said (new window) it doesn't have specific guidance on prescribing oral BPC-157, but expects licensees to exercise professional judgment to ensure they are providing safe and appropriate patient care
Transition Phase After the first phase, clients may transition to weekly injections for a few weeks
Over-the-counter supplements typically contain 102,000 micrograms per dosefar exceeding physiological requirements
Dose reduction community sources describe halving the per-injection dose when flushing or metallic taste becomes too intrusive, then re-evaluating at 2 weeks
